At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Hong Kong based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Chief Financial Officer of WuXi AppTec
Prior to joining JHL Biotech, Ellis was a Managing Director and the Head of Greater China at Ion Pacific, an Asia-focused VC Merchant Bank. Prior to Ion Pacific, Ellis was an investment banker and Head of China Mergers & Acquisitions at Bank of America Merrill Lynch. Ellis began his finance career in New York before transferring to Asia with Lehman Brothers in 2007. He has also held senior investment banking positions at Citigroup, Nomura and Lehman Brothers advising on transaction across multiple sectors including healthcare.
Follow Ellis Chu:
About WuXi AppTec: WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
CFO of Prenetics
Stephen is the Chief Financial Officer of Prenetics, and oversees the accounting, finance, and operations functions.Before joining Prenetics, Stephen was a Vice President in the Asia Pacific Investment Banking team of Citigroup, where he completed initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the US. Prior to investment banking, Stephen was a senior auditor with Ernst & Young. Stephen graduated from Yale University’s School of Management, the London School of Economics and Political Science and Hong Kong Baptist University. He is a Certified Public Accountant and has completed the CFA Program.
Follow Stephen Lo:
About Prenetics: Prenetics is a genetic and diagnostic health testing company that helps identify health risks with the use of a DNA sequencing technology.
Chief Financial Officer of Alphamab Oncology
Prior to Alphamab Oncology, Mr. Terry Shuai was the head of Healthcare, Asia at Deutsche Bank. He has more than 11 years of experience in investment banking in Hong Kong, and extensive experience in healthcare-related capital market transactions and M&As. Terry previously worked at Bain Capital, Morgan Stanley, Credit Suisse and HSBC. Mr. Shuai holds an M.B.A. from the University of Chicago (Honors); a Master of Chemistry from Columbia University; and a B.S. in Polymer Science from the University of Science and Technology of China.
Follow Terry Shuai:
About Alphamab Oncology: Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Chief Financial Officer of I-Mab Biopharma
As the Chief Financial Officer, Jielun Zhu, MBA, CFA, is in charge of the overall financial strategy and management, capital investment, corporate finance and investor relations. He is a veteran and expert in the finance industry, with over 11 years of experience in investment banking. From December 2015 to July 2018, prior to joining I-Mab, he served as a managing director and Asia Head of Healthcare Investment Banking and Capital Markets in Hong Kong for Jefferies Group LLC, a global full-service investment bank with a strong focus in healthcare. At Jefferies, he advised many biotechnology and healthcare clients globally on IPOs and other financings, as well as mergers and acquisitions. From August 2008 to September 2015, he worked for the Deutsche Bank Group in its Hong Kong office. He occupied a succession of positions, with the last one being Director in the Corporate Finance Division, which entailed working with leading clients in the healthcare and other sectors in Greater China. From July 2007 to July 2008, he was an investment banker in Hong Kong with UBS AG. Before investment banking, Jielun Zhu was a strategy consultant in Boston focused on serving clients in the US pharmaceutical and biotechnology industry. Jielun Zhu earned his M.B.A. from the Harvard Business School with distinction in June 2007 and his Bachelor of Arts degree with honors in mathematics-economics from Wesleyan University. He is also a CFA charter holder.
Follow Jielun Zhu:
About I-Mab Biopharma: I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
EVP & Chief Financial Officer of Hua Medicine
Mr. George Lin, J.D., a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally. Prior to joining Hua Medicine, he was Asia Pacific Head of Consumer, Retail and Healthcare Investment Banking and Head of Hong Kong and Taiwan Investment Banking for Bank of America Merrill Lynch based in Hong Kong. As an investment banker and corporate lawyer focused on healthcare, retail and the consumer sectors, Mr. Lin was previously based in Los Angeles and San Francisco before moving to Hong Kong in 2007. His experience entails IPOs, debt and equity financings and M&As for leading companies in Asia, the United States and Europe. In the last 10 years alone, Mr. Lin has led M&A transactions valued (in aggregate) in excess of US$20 billion and raised financings valued (in aggregate) at over US$40 billion. Since April 2018, Mr. Lin has served as a member of the Biotech Advisory Panel of the Hong Kong Stock Exchange. Prior to Bank of America Merrill Lynch, Mr. Lin also worked at Credit Suisse as an investment banker in their Hong Kong, San Francisco and Los Angeles offices, and at O’Melveny & Myers LLP as a corporate attorney in their Los Angeles Office. Mr. Lin currently serves as a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. Mr. Lin received a Bachelor of Sciences degree in Biological Sciences from the University of California at Davis and a Juris Doctor degree from The University of Chicago Law School.
Follow George Lin:
About Hua Medicine: Hua Medicine is a clinical-stage, innovative drug development company in China.
CFO of Arbele Corp.
Follow Rita Lun:
About Arbele Corp.: Arbele Corp is a biotech R&D company focusing on next-gen immunotherapeutic platforms to treat cancer of high mortality